
    
      The study was prematurely discontinued on 06Nov2012 due to tolerability findings in patients
      treated in Part I of the study that have prompted the Sponsor to re-evaluate the strategic
      development of the program. An unexpected frequency of arterial thrombotic events (ATEs) and
      venous thrombotic events (VTEs) were reported in patients treated in Part I.
    
  